Navigation Links
Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
Date:12/23/2010

FRAZER, Pa., Dec. 23, 2010 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that its Board of Directors has appointed J. Kevin Buchi as Chief Executive Officer and a member of the company's Board. The Board will address the role of company Chairman in the future. William P. Egan will continue to serve as Cephalon's independent Presiding Director.

"Kevin is an experienced pharmaceutical executive who has been involved in every aspect of running our business," said Mr. Egan. "Over the course of many years, Kevin worked closely with Frank Baldino, Jr., to create the company that we know today, and he has the passion, leadership skills, organizational abilities and unwavering commitment to patients that are critical to ensuring Cephalon's continued growth and success. He is the clear choice to lead our company."  

Mr. Buchi, who has been with Cephalon for almost 20 years, assumed day-to-day chief executive responsibilities for the company in August 2010. He previously served as a member of the Cephalon executive management team in the roles of Chief Operating Officer and Chief Financial Officer. Additionally, for the last seven years, he has led the business development function with responsibility for mergers, acquisitions and in-licensing of products.

Commenting on his appointment as CEO, Mr. Buchi said, "I am honored to be named Chief Executive Officer and to continue the work of Frank Baldino. I had the privilege to work with Frank as we crafted the strategy for leading and growing Cephalon. I intend to continue the same strategic course for the company." Mr. Buchi added, "Cephalon is an extraordinary company with one of the most robust pipelines in the industry focused on patients suffering from rare disorders and diseases for which there are no cures. We have expanded our global footprint dramatically in the last few years. I
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon to Webcast Investor Day
2. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
3. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
4. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
5. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
6. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
7. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
8. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
9. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
11. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
(Date:3/2/2015)... 2, 2015  Akron Children,s Hospital has been designated ... American College of Radiology (ACR), making it the first ... second children,s hospital in the United States ... "Earning recognition from the ACR as a DICOE provides ... level compared with national benchmarks," says Dr. Michael ...
(Date:3/2/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, ... Allowance from the U.S. Patent and Trademark Office ... Compositions and methods to improve the therapeutic benefit ...
Breaking Medicine Technology:Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4
... NEW YORK, March 21, 2011 The Alzheimer,s Drug ... grant of $170,750 to ADispell Inc. to develop small ... loss that occurs with Alzheimer,s Disease. ... licensed technology from Cornell University to develop neuroprotective drug ...
... LLC , ( www.curemark.com ), a drug research and development ... the company has completed its targeted enrollment of Phase III ... Curemark has reached its targeted enrollment for the study ... CM-AT Phase III trial at 18 sites across the country. ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease 2Curemark Completes Enrollment of Phase III Autism Trials 2
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... Administration (FDA) warned against the use of power ... and fibroid removal surgeries, insurer UnitedHealthCare is poised ... use of those devices. In a notification sent ... beginning in April, it would require pre-authorization for ...
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... of Idoll Magazine, a medium for the model agency ... can find, and buy Mango, Passion Fruit, Pink Grapefruit, ... March 3rd, 2015, after 1pm. , At a cost ... has recently came under fire by announcing the brands ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. Alex ... involve one or several procedures to reduce the appearance of ... a more even gum line. Dr. Farnoosh is the creator ... can permanently lighten discolored or naturally dark gums. , ... personalized treatment plan to address a patient’s specific needs based ...
(Date:3/2/2015)... Minnetonka, MN (PRWEB) March 02, 2015 ... accredited temperature calibration for Secondary Standard Platinum ... (RTDs) in 5 business days or less . ... is NVLAP ® Accredited (Lab Code 200706-0), ... NIST traceability. Temperature range is -196°C to ...
(Date:3/2/2015)... Over the last five years the ultrasound market ... expand their geographic presence and achieve economies of scale. ... billion by 2019 at CAGR of 5.1% from 2014 ... Canada and a major part of Europe are mature ... Asia-Pacific including China and India, Latin America and the ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... a company developing breakthrough molecular imaging agents ... announced today that the United States Patent ... 7,438,891, covering methods of imaging cardiovascular plaque ... patent, exclusively licensed from the Massachusetts General ...
... Increased 2% and Increased 1% Excluding the Impact of Foreign ... Decreased 7% and Decreased 1% Excluding the Impact of Foreign ... Increase Led by Growth in Excess of 10% for Prevnar, ... Jan. 26 Wyeth (NYSE: WYE ) today ...
... Saint Joseph,s Health System announced,that it has launched ... a,non-profit training center for robotic surgical teams from around ... Thoracic Surgeons (STS) annual,meeting in San Francisco. , ... to patients from robotic-assisted,surgery since we began our program ...
... To Stay Happy and Healthy This WinterSAN JOSE, Calif., ... avoiding the "winter blues" is to set small goals, ... and exercising, for a well-rounded approach to life. This ... Day of the Year," January 26, 2009, designated by ...
... Jan. 26 Concentric Medical, Inc., the global leader ... today announced that the company,s Merci Retrieval System(TM) has ... in August 2004. The Merci Retrieval System is ... to remove blood clots from patients suffering an ischemic ...
... Internal Manufacturing Scale-Up Underway to Support Increased Product ... (OTC Bulletin Board: BLFS), a leading developer and ... media products for cells, tissues, and organs, today ... full year 2008 and also the receipt of ...
Cached Medicine News:Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 3Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 4Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 5Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 6Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 7Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 8Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 9Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 10Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 11Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 12Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 13Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 14Health News:Saint Joseph's Launches International College of Robotic Surgery 2Health News:Natural Solutions for the Most Depressing Day of the Year 2Health News:Natural Solutions for the Most Depressing Day of the Year 3Health News:Natural Solutions for the Most Depressing Day of the Year 4Health News:Natural Solutions for the Most Depressing Day of the Year 5Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 2Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 3
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... cost-effective method of providing patient warming while ... warming tube is ideal for use in ... Radiology. The CSZ Warming Tube is the ... it may be used in almost any ...
... Our patient warming system consists of ... a range of blankets for use ... all clinical applications. Blankets are available ... adult and paediatric sizes and a ...
... is the automated benchtop solution for nucleic ... extensive integrated features and a sample throughput ... the system meets the demanding nucleic acid ... to medium sample throughput., ,The high-quality nucleic ...
Medicine Products: